Takeda Pharmaceutical Company Limited (TAK)
USD 13.11
(-1.87%)
USD 13.11
(-1.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 144.06 Billion JPY | -54.56% |
| 2023 | 317.01 Billion JPY | 37.8% |
| 2022 | 230.05 Billion JPY | -38.81% |
| 2021 | 376 Billion JPY | 749.9% |
| 2020 | 44.24 Billion JPY | -59.46% |
| 2019 | 109.12 Billion JPY | -41.61% |
| 2018 | 186.88 Billion JPY | 62.59% |
| 2017 | 114.94 Billion JPY | 43.38% |
| 2016 | 80.16 Billion JPY | 154.99% |
| 2015 | -145.77 Billion JPY | -236.68% |
| 2014 | 106.65 Billion JPY | -18.73% |
| 2013 | 131.24 Billion JPY | 5.7% |
| 2012 | 124.16 Billion JPY | -49.91% |
| 2011 | 247.86 Billion JPY | -16.75% |
| 2010 | 297.74 Billion JPY | 27.03% |
| 2009 | 234.38 Billion JPY | -34.06% |
| 2008 | 355.45 Billion JPY | 5.85% |
| 2007 | 335.8 Billion JPY | 7.2% |
| 2006 | 313.24 Billion JPY | 12.91% |
| 2005 | 277.43 Billion JPY | -2.74% |
| 2004 | 285.26 Billion JPY | 4.97% |
| 2003 | 271.76 Billion JPY | 15.32% |
| 2002 | 235.65 Billion JPY | 60.47% |
| 2001 | 146.85 Billion JPY | 22.76% |
| 2000 | 119.62 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 89.39 Billion JPY | 3256.0% |
| 2024 Q3 | 105.72 Billion JPY | 320.11% |
| 2024 FY | 144.06 Billion JPY | -54.56% |
| 2024 Q4 | -3.01 Billion JPY | -102.85% |
| 2024 Q2 | -48.03 Billion JPY | -3.36% |
| 2023 Q1 | 105.01 Billion JPY | 1023.2% |
| 2023 Q3 | 119.12 Billion JPY | 92.94% |
| 2023 FY | 317.01 Billion JPY | 37.8% |
| 2023 Q4 | 31.13 Billion JPY | -73.86% |
| 2023 Q2 | 61.74 Billion JPY | -41.21% |
| 2022 FY | 230.05 Billion JPY | -38.81% |
| 2022 Q3 | 57.77 Billion JPY | 25.69% |
| 2022 Q1 | 137.68 Billion JPY | -30.14% |
| 2022 Q4 | -11.37 Billion JPY | -119.69% |
| 2022 Q2 | 45.96 Billion JPY | -66.62% |
| 2021 Q2 | 4.03 Billion JPY | -95.11% |
| 2021 Q3 | 92.35 Billion JPY | 2187.81% |
| 2021 Q4 | 197.09 Billion JPY | 113.4% |
| 2021 FY | 376 Billion JPY | 749.9% |
| 2021 Q1 | 82.51 Billion JPY | 4686.02% |
| 2020 Q1 | -20.66 Billion JPY | 62.65% |
| 2020 Q3 | -32.22 Billion JPY | -159.84% |
| 2020 Q4 | 1.72 Billion JPY | 105.35% |
| 2020 FY | 44.24 Billion JPY | -59.46% |
| 2020 Q2 | 53.84 Billion JPY | 360.62% |
| 2019 Q3 | 37.76 Billion JPY | -22.01% |
| 2019 Q4 | -55.3 Billion JPY | -246.45% |
| 2019 FY | 109.12 Billion JPY | -41.61% |
| 2019 Q2 | 48.42 Billion JPY | -38.11% |
| 2019 Q1 | 78.24 Billion JPY | 244.84% |
| 2018 Q2 | 28.02 Billion JPY | -80.64% |
| 2018 FY | 186.88 Billion JPY | 62.59% |
| 2018 Q4 | -54.02 Billion JPY | -179.34% |
| 2018 Q3 | 68.08 Billion JPY | 142.93% |
| 2018 Q1 | 144.78 Billion JPY | 385.39% |
| 2017 Q1 | 99.52 Billion JPY | 397.27% |
| 2017 FY | 114.94 Billion JPY | 43.38% |
| 2017 Q4 | -50.73 Billion JPY | -222.62% |
| 2017 Q3 | 41.37 Billion JPY | 67.01% |
| 2017 Q2 | 24.77 Billion JPY | -75.11% |
| 2016 Q1 | 24.58 Billion JPY | 110.9% |
| 2016 FY | 80.16 Billion JPY | 154.99% |
| 2016 Q3 | 59.26 Billion JPY | 98.85% |
| 2016 Q2 | 29.8 Billion JPY | 21.23% |
| 2016 Q4 | -33.48 Billion JPY | -156.5% |
| 2015 Q3 | 18.3 Billion JPY | -34.7% |
| 2015 FY | -145.77 Billion JPY | -236.68% |
| 2015 Q4 | -225.52 Billion JPY | -1331.81% |
| 2015 Q2 | 28.03 Billion JPY | -16.05% |
| 2015 Q1 | 33.39 Billion JPY | 869.56% |
| 2014 Q2 | 42.8 Billion JPY | 47.21% |
| 2014 Q3 | 54.53 Billion JPY | 27.4% |
| 2014 Q4 | -4.34 Billion JPY | -107.96% |
| 2014 FY | 106.65 Billion JPY | -18.73% |
| 2014 Q1 | 29.07 Billion JPY | 479.19% |
| 2013 Q4 | -7.66 Billion JPY | -140.1% |
| 2013 FY | 131.24 Billion JPY | 5.7% |
| 2013 Q1 | 87.56 Billion JPY | 340.26% |
| 2013 Q2 | 32.22 Billion JPY | -63.2% |
| 2013 Q3 | 19.12 Billion JPY | -40.66% |
| 2012 Q1 | 75.58 Billion JPY | 133.46% |
| 2012 Q4 | -36.44 Billion JPY | -246.09% |
| 2012 Q3 | 24.94 Billion JPY | -58.47% |
| 2012 Q2 | 60.07 Billion JPY | -20.52% |
| 2012 FY | 124.16 Billion JPY | -49.91% |
| 2011 Q4 | 32.37 Billion JPY | -54.58% |
| 2011 Q1 | 64.11 Billion JPY | 66.11% |
| 2011 Q2 | 80.1 Billion JPY | 24.94% |
| 2011 Q3 | 71.28 Billion JPY | -11.01% |
| 2011 FY | 247.86 Billion JPY | -16.75% |
| 2010 FY | 297.74 Billion JPY | 27.03% |
| 2010 Q3 | 69.51 Billion JPY | -9.77% |
| 2010 Q2 | 77.04 Billion JPY | -31.58% |
| 2010 Q4 | 38.59 Billion JPY | -44.48% |
| 2010 Q1 | 112.59 Billion JPY | 71.08% |
| 2009 Q4 | 65.81 Billion JPY | -32.0% |
| 2009 FY | 234.38 Billion JPY | -34.06% |
| 2009 Q2 | 69.29 Billion JPY | 0.0% |
| 2009 Q3 | 96.78 Billion JPY | 39.67% |
| 2008 FY | 355.45 Billion JPY | 5.85% |
| 2007 FY | 335.8 Billion JPY | 7.2% |
| 2006 FY | 313.24 Billion JPY | 12.91% |
| 2005 FY | 277.43 Billion JPY | -2.74% |
| 2004 FY | 285.26 Billion JPY | 4.97% |
| 2003 FY | 271.76 Billion JPY | 15.32% |
| 2002 FY | 235.65 Billion JPY | 60.47% |
| 2001 FY | 146.85 Billion JPY | 22.76% |
| 2000 FY | 119.62 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | -83.99 Million USD | 171622.627% |
| Bausch Health Companies Inc. | -592 Million USD | 24435.642% |
| Catalent, Inc. | -1.04 Billion USD | 13912.752% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 19043.721% |
| Elanco Animal Health Incorporated | -1.23 Billion USD | 11803.249% |
| Perrigo Company plc | -12.7 Million USD | 1134485.827% |
| Teva Pharmaceutical Industries Limited | -559 Million USD | 25872.272% |
| Zoetis Inc. | 2.34 Billion USD | -6046.203% |